SCHEMBL12961328

SCHEMBL12961328

CNC1CCN(c2ccc([N+](=O)O)c(OC)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.52
▸ LMNA P02545 2/20 0.52
▸ MAPT P10636 9/20 0.51
▸ SIRT6 Q8N6T7 2/20 0.50
▸ EGFR P00533 1/20 0.42
▸ SUV39H2 Q9H5I1 3/20 0.41
▸ ZAP70 P43403 1/20 0.40
▸ SSTR5 P35346 1/20 0.39
▸ MAPK1 P28482 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ ALK Q9UM73 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23654833 0.88 ALDH1A1 (0.70) ALDH1A1LMNAMAPTSIRT6MAPK1
SCHEMBL12856233 0.81 ALDH1A1 (0.52) ALDH1A1LMNAMAPTSIRT6CYP1A2
SCHEMBL12312068 0.81 ALDH1A1 (0.63) ALDH1A1LMNAMAPTSIRT6MAPK1
SCHEMBL12862130 0.80 SIRT6 (0.75) ALDH1A1LMNAMAPTSIRT6MAPK1
SCHEMBL12312000 0.79 DPP4 (0.45) ALDH1A1LMNAMAPTEGFRSUV39H2
SCHEMBL13380460 0.78 SUV39H2 (0.44) ALDH1A1LMNAMAPTEGFRSUV39H2
SCHEMBL16431871 0.78 SUV39H2 (0.47) ALDH1A1LMNAMAPTEGFRSUV39H2
SCHEMBL517295 0.78 ALDH1A1 (0.70) ALDH1A1LMNAMAPTSIRT6MAPK1
SCHEMBL517280 0.76 ALDH1A1 (0.64) ALDH1A1LMNAMAPTSIRT6MAPK1
SCHEMBL517279 0.76 ALDH1A1 (0.64) ALDH1A1LMNAMAPTSIRT6MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275413-A1 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. Novartis AG (CH) 2011-01-19 — — EP disclosed
Send feedback